Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Spotlight on Clinical Response

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

Udai Banerji, Annette Affolter, Ian Judson, Richard Marais and Paul Workman
Udai Banerji
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annette Affolter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Judson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Marais
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Workman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-08-0145 Published April 2008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: March 2008 to January 2021

AbstractFull-text HTMLPDF
Total5268136393717

Cited By

Article Information

Volume 7, Issue 4, pp. 737-739

DOI 
https://doi.org/10.1158/1535-7163.MCT-08-0145
PubMed 
18375819

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • February 26, 2008
  • February 19, 2008
  • Published first March 28, 2008.

Article Versions

  • Previous version (March 28, 2008 - 12:24).
  • Previous version (March 31, 2008 - 11:40).
  • You are viewing the most recent version of this article.
Copyright & Usage 
American Association for Cancer Research

Author Information

  1. Udai Banerji12,
  2. Annette Affolter3,
  3. Ian Judson12,
  4. Richard Marais3 and
  5. Paul Workman1
  1. 1Signal Transduction and Molecular Pharmacology Team and Clinical Pharmacology Team, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 2The Royal Marsden Hospital, Sutton, United Kingdom; and 3Signal Transduction Team, Cancer Research UK Centre for Cell and Molecular Biology, The Institute of Cancer Research, London, United Kingdom
  1. Requests for reprints: Paul Workman, Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom. Phone: 44-20872-24301; Fax: 44-20872-24324.
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 7 (4)
April 2008
Volume 7, Issue 4
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors
Udai Banerji, Annette Affolter, Ian Judson, Richard Marais and Paul Workman
Mol Cancer Ther April 1 2008 (7) (4) 737-739; DOI: 10.1158/1535-7163.MCT-08-0145

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors
Udai Banerji, Annette Affolter, Ian Judson, Richard Marais and Paul Workman
Mol Cancer Ther April 1 2008 (7) (4) 737-739; DOI: 10.1158/1535-7163.MCT-08-0145
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Intratumoral Molecular Heterogeneity
  • Erlotinib Response EGFR+ NSCLC with Squamous Element
  • Chondrosarcoma and TRAIL Targeted Therapy
Show more Spotlight on Clinical Response
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement